WESTPORT, Conn., July 17, 2017 -- Real Endpoints (RE), a data, analytics, and advisory company that helps payers and biopharma companies define the value and economic impact of new pharmaceuticals and value-based approaches to reimbursement, announced today that Jane F. Barlow, MD, MPH, MBA, a 25-year veteran of healthcare payers, has joined the company as Executive Vice President and Chief Clinical Officer. Dr. Barlow will lead RE’s advisory work as well as applications of its assessment tools.
Dr. Barlow joins RE from CVS Health, where she was Associate Chief Medical Officer, Chief Medical Officer for Government Services and a Board Director for SilverScripts Insurance Company. A seasoned clinical and strategic executive, Barlow is a recognized expert in payer reimbursement, policy, technology, quality and compliance, benefits design and population health management.
“I'm incredibly excited to be joining Real Endpoints at a time when clinical innovations need to deliver the highest value for every dollar spent,” said Dr. Barlow. “This challenge requires new models and expanded thinking. RE has built an extraordinary foundation of credibility, thanks to its analytics tools and its close, trusted working relationships with both biopharma and payers – creating a major opportunity to facilitate thoughtful change. The potential of this transformation, and the chance to help lead it, is enormously energizing.”
“Jane brings to RE and its clients practical, real-world creativity in solving the issues of trust, predictability and value that keep biopharma innovators and payers at loggerheads,” said Roger Longman, CEO of RE. “RE is dedicated to breaking that logjam for the medical and economic benefit of patients and our healthcare system, and Jane will play an essential role in helping us do so.”
As a senior member of the RE team, Dr. Barlow will advise on all clinical and strategic aspects of payer reimbursement, including value-based contracting, as well as applying RE’s unique tool kit to solving its clients’ challenges. She will help RE serve as an independent voice collaborating with payers, manufacturers and vendors to optimize healthcare outcomes and control costs.
Prior to joining CVS Health, Dr. Barlow was VP, Clinical Innovation at Medco Health Solutions. She also led the Personalized Medicine Business Solutions group, was responsible for quality and accreditation, and served as medical director for Medco’s employer, labor and government accounts.
Previously, Dr. Barlow was a senior health management leader at IBM, shaping and delivering over $2 billion annually in health benefits, employee wellness and well-being programs. Her diverse background also includes positions with the U.S. military, federal government, industry and private practice.
Dr. Barlow attended medical school at Creighton University and completed her residency training in occupational medicine at The Johns Hopkins University. She is board-certified in occupational medicine and a fellow of both the American College of Occupational and Environmental Medicine and the American College of Preventive Medicine.
ABOUT REAL ENDPOINTS
Real Endpoints, a data, analytics, and advisory firm, helps payers and biopharma companies define the value and economic impact of pharmaceuticals. RE’s web-based tools deliver drug-value assessments for both pipeline and marketed drugs (RxScorecard), credible and independent budget impact analyses by payer segment (Payer Impact), and value-based contracting templates. The tools also power our uniquely objective and insightful advisory work. Our subsidiary, Reimbursement Intelligence (RI), offers a range of diagnostics and training and communication services to strengthen market access programs, communications and people.
Learn more at www.realendpoints.com
Contact: Viviana Ramos E-Mail: [email protected] Phone: 203.517.4769


TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



